PRLD: KAT6A degrader and JAK2 program set the next clinical milestones
According to TradingView, PRLD advances its KAT6A and JAK2 programs; KAT6 data are due in H2 2027, and an Incyte option could bring $100M.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Prelude Therapeutics (PRLD) is building its portfolio around JAK2 JH2, a selective KAT6A degrader and mCALR. The JAK2 candidate is already in the clinic, and enrollment for the KAT6 study is expected soon. Early data showing proof of concept for KAT6 are planned for the second half of 2027.
Separately, TradingView notes that an Incyte option exercise could provide the company with $100M in non-dilutive financing. The summary is labeled as AI-generated by TradingView, which warns it may contain inaccuracies, so readers should verify details with the original source.
why it matters
For investors, the key points are the timing of clinical milestones and a possible funding inflow that would not dilute shareholders. The story concerns a single company in a narrow biotech niche, so its impact on the broader market is limited.
tags
instruments
sources
- PRLD: Selective KAT6A degradation and JAK2 execution anchor the pipeline’s next clinical milestones — TradingView, 20 October 2026 at 19:05 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗